Profile data is unavailable for this security.
About the company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
- Revenue in USD (TTM)355.40m
- Net income in USD-208.59m
- Incorporated1991
- Employees536.00
- LocationBioCryst Pharmaceuticals Inc4505 Emperor Blvd Ste 200DURHAM 27703-8457United StatesUSA
- Phone+1 (919) 859-1302
- Fax+1 (919) 859-1314
- Websitehttps://www.biocryst.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 1.28bn | 171.00 | -- | 2.11 | -- | 62.69 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Cullinan Therapeutics Inc | 0.00 | -132.35m | 1.29bn | 85.00 | -- | 2.27 | -- | -- | -3.14 | -3.14 | 0.00 | 9.88 | 0.00 | -- | -- | 0.00 | -27.85 | -12.37 | -29.31 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Akero Therapeutics Inc | 0.00 | -179.27m | 1.33bn | 58.00 | -- | 1.57 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 517.46m | 30.57m | 1.36bn | 642.00 | 40.62 | 3.01 | 14.49 | 2.62 | 1.59 | 1.59 | 27.12 | 22.71 | 0.6161 | 1.77 | 2.98 | 806,012.40 | 4.23 | -2.83 | 5.02 | -3.35 | 62.71 | 60.18 | 6.87 | -6.15 | 3.12 | 3.67 | 0.3745 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.37bn | 297.00 | 226.76 | 3.17 | 126.19 | 4.54 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| BioCryst Pharmaceuticals Inc | 355.40m | -208.59m | 1.39bn | 536.00 | -- | -- | -- | 3.91 | -1.07 | -1.07 | 1.81 | -2.31 | 0.727 | 0.1787 | 6.51 | 663,050.40 | -42.67 | -47.95 | -54.00 | -64.89 | 98.56 | 97.06 | -58.69 | -114.94 | 3.48 | -1.00 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Pacira Biosciences Inc | 681.75m | 70.47m | 1.42bn | 711.00 | 23.55 | 1.59 | 9.80 | 2.08 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Soleno Therapeutics Inc | 0.00 | -52.03m | 1.42bn | 33.00 | -- | 9.53 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Vir Biotechnology Inc | 79.60m | -539.44m | 1.44bn | 587.00 | -- | 0.9288 | -- | 18.08 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Xencor Inc | 162.18m | -133.36m | 1.45bn | 280.00 | -- | 2.36 | -- | 8.93 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.45bn | 58.00 | 15.44 | 1.80 | 10.99 | 12.27 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Arcus Biosciences Inc | 237.00m | -231.00m | 1.46bn | 577.00 | -- | 2.06 | -- | 6.14 | -3.10 | -3.10 | 3.07 | 7.78 | 0.1861 | -- | 6.24 | 410,745.20 | -18.14 | -15.85 | -21.35 | -18.25 | -- | -- | -97.47 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.47bn | 1.60k | -- | 0.4102 | -- | 1.98 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.121 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -32.61m | 1.48bn | 20.00 | -- | 15.06 | -- | -- | -1.18 | -1.18 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -46.26 | -- | -46.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Avadel Pharmaceuticals PLC (ADR) | 55.14m | -156.83m | 1.49bn | 154.00 | -- | 18.95 | -- | 26.95 | -1.86 | -1.86 | 0.6334 | 0.8157 | 0.3573 | -- | 4.80 | 358,058.40 | -101.63 | -40.21 | -172.85 | -47.99 | 95.71 | -- | -284.42 | -374.75 | 2.60 | -14.71 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to BioCryst Pharmaceuticals Inc's reporting currency: US Dollar USD
46.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 17.48m | 8.48% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 17.18m | 8.34% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 15.52m | 7.53% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 13.05m | 6.33% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 10.13m | 4.91% |
| Kynam Capital Management LPas of 31 Mar 2024 | 6.53m | 3.17% |
| Geode Capital Management LLCas of 31 Mar 2024 | 4.40m | 2.14% |
| Alkeon Capital Management LLCas of 31 Mar 2024 | 4.10m | 1.99% |
| RP Management LLC (Investment Management)as of 31 Mar 2024 | 3.85m | 1.87% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 3.50m | 1.70% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
